STOCK TITAN

Wellington discloses 4.4M Kymera (KYMR) shares in Schedule 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. received an updated ownership report from several Wellington entities on a Schedule 13G/A. Wellington Management Group LLP and related entities report beneficial ownership of 4,412,933 shares of Kymera common stock, representing about 5.53% of the outstanding class.

The filing shows no sole voting or dispositive power, with voting and investment authority shared among Wellington affiliates and their advisory clients. The securities are held in the ordinary course of business, and Wellington states they are not held for the purpose of changing or influencing control of Kymera.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Management Company LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026

FAQ

What percentage of Kymera (KYMR) does Wellington report owning?

Wellington-affiliated entities report beneficial ownership of about 5.53% of Kymera Therapeutics’ common stock. This stake is disclosed in a Schedule 13G/A filing, indicating a significant but non‑controlling institutional position held for ordinary course investment purposes.

How many Kymera (KYMR) shares are beneficially owned by Wellington?

Wellington entities report beneficial ownership of 4,412,933 shares of Kymera common stock. These shares are held on behalf of advisory clients of various Wellington investment advisers, with voting and dispositive powers shared rather than held solely by a single entity.

Which Wellington entities are reporting ownership in Kymera (KYMR)?

The reporting persons are Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP. Together, they report aggregated beneficial ownership of Kymera common stock on behalf of their investment advisory clients.

Does Wellington seek to influence control of Kymera (KYMR) with this stake?

Wellington certifies the Kymera shares were acquired and are held in the ordinary course of business. The filing states they are not held for the purpose or effect of changing or influencing control of Kymera, consistent with a passive institutional investment.

Who ultimately benefits from the Kymera (KYMR) shares held by Wellington?

The Kymera shares disclosed are owned of record by clients of Wellington investment advisers. These clients have rights to dividends and sale proceeds. No single client is known to hold more than five percent of Kymera’s common stock through these managed accounts.

What voting and dispositive powers does Wellington report over Kymera (KYMR) shares?

The Wellington entities report no sole voting or dispositive power over Kymera shares. Instead, they disclose shared voting and shared dispositive power across affiliates and advisory relationships, reflecting the structure of their investment management business and client accounts.
Kymera Therapeutics, Inc.

NASDAQ:KYMR

KYMR Rankings

KYMR Latest News

KYMR Latest SEC Filings

KYMR Stock Data

6.32B
76.74M
2.53%
109.99%
11.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN